HEALTH● LOW1h ago · Oct 21, 2026, 1:23 PM

Roivant to seek label expansion for Lisraya in uveitis after late-stage trial win

Seeking Alpha Tech · global

Roivant intends to seek expanded approval for its drug Lisraya for treating uveitis, following successful late-stage trial results. This is significant for patients with uveitis and for the pharmaceutical company's product portfolio.

Read at Seeking Alpha Tech Ask the Analyst about this

GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.

See it on the live mapEvents around the world right now

More in Health

HEALTH33m agoThe fitness test that allows you to assess your risk of deathBBC Afrique HEALTH36m agoReps pass organ transplantation bill for second readingVanguard Nigeria HEALTH38m agoMenopause is having its overdue momentThe Hill HEALTH1h agoHow To Protect Yourself From Ebola InfectionChannels TV